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IMPORTANCE Few studies have compared the use of methotrexate and biologics, the most
commonly used systemic medications for treatment of moderate to severe psoriasis in children.
OBJECTIVE To assess the real-world, 6-month reduction in psoriasis severity and long-term
drug survival (rate and duration of adherence to a specific drug) of methotrexate vs biologics
in plaque psoriasis in children.
DESIGN, SETTING, AND PARTICIPANTS A retrospective medical records review was conducted
at 20 European and North American centers. Treatment response was based on site-reported
Psoriasis Area and Severity Index (PASI) and/or Physician Global Assessment (PGA) scores at
baseline and within the first 6 months of treatment. Participants included all 234 consecutively
seen children with moderate to severe psoriasis who received at least 3 months of methotrexate
or biologics from December 1, 1990, to September 16, 2014, with sufficient data for analysis.
Data analysis was performed from December 14, 2015, to September 1, 2016.
MAIN OUTCOMES AND MEASURES PASI, with a range from 0 to 72 (highest score indicating
severe psoriasis), and/or PGA, with a scale of 0 (clear), 1 (minimal), 2 (mild), 3 (moderate),
4 (severe), and 5 (very severe).
RESULTS Of 234 pediatric patients (103 boys [44.0%]; 131 girls [56.0%]) treated with
methotrexate and/or biologics, 163 patients (69.7%) exclusively received methotrexate,
47 patients (20.1%) exclusively received biologics, and 24 children (10.2%) received
methotrexate and biologics sequentially. Of the latter cohort, 23 children were treated
initially with methotrexate. Mean (SD) age at initiation was 11.6 (3.7) years for methotrexate
and 13.3 (2.9) years for biologics (73.2% for etanercept) (P = .002). Among patients
evaluated by a scoring method at 6-month follow-up, 75% or greater improvement in PASI
(PASI75) was achieved in 12 of 30 patients (40.0%) receiving methotrexate and 20 of 28
patients (71.4%) receiving biologics, and PGA was clear/almost clear (PGA 0/1) in 41 of 115
patients (35.6%) receiving methotrexate and 18 of 37 patients (48.6%) receiving biologics.
Achieving PASI75 and/or PGA 0/1 between baseline and 6 months was more likely with
biologics than methotrexate (PASI75: odds ratio [OR], 4.56; 95% CI, 2.02-10.27; P < .001;
and PGA 0/1: OR, 2.00; 95% CI, 0.98-4.00; P = .06). Decreased mean PASI and PGA scores
were associated with biologics more than with methotrexate (PASI effect, −3.13; 95% CI,
−4.33 to −1.94; P < .001; and PGA effect, −0.31; 95% CI, −0.56 to −0.06; P = .02). After 1, 3,
and 5 years of use, overall drug survival rates for methotrexate were 77.5%, 50.3%, and
35.9%, and for biologics, the rates were 83.4%, 64.3%, and 57.1%, respectively. Biologics
were associated with a better confounder-corrected drug survival than methotrexate
(hazard ratio [HR], 2.23; 95% CI, 1.21-4.10; P = .01). Discontinuation owing to lack of
response was comparable (HR, 1.64; 95% CI, 0.80-3.36; P = .18).
CONCLUSIONS AND RELEVANCE Methotrexate and biologics appear to be associated with
improvement in pediatric psoriasis, although biologics seem to be associated with greater
reduction in psoriasis severity scores and higher drug survival rates than methotrexate
in the real-world setting. Additional studies directly comparing these medications should
be performed for confirmation.
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P soriasis is a chronic inflammatory skin disorder that af-fects up to 1.37% of children. Most children affected bypsoriasis have plaque psoriasis.1,2 Pediatric psoriasis is
often highly visible and uncomfortable, contributing to im-
paired quality of life and necessitating effective therapy. Al-
though most children affected by psoriasis have mild psoria-
sis that is responsive to topical therapy, approximately 20%
of children have moderate to severe disease that may require
phototherapy or systemic therapy.3
The paucity of approved agents and direct comparative
data among options complicates selection of the optimal sys-
temic medication for individual patients. Methotrexate is the
most commonly prescribed and least expensive systemic agent
internationally.4 Two small, prospective studies of children
with plaque psoriasis (longitudinal registry,5 n = 25 and metho-
trexate arm of comparative trial vs adalimumab,6 n = 37)
showed that methotrexate was associated with improve-
ment and well tolerated. Targeted therapies, including etaner-
cept, adalimumab (tumor necrosis factor inhibitors), and
ustekinumab (IL-12/23 inhibitor), have demonstrated effi-
cacy and safety in pediatric plaque psoriasis in randomized
placebo-controlled trials.6-10
The European Medicines Agency approved etanercept for
plaque psoriasis in children (age 6-17 years) in 2008,7-9,11 adali-
mumab (age ≥4 years) in 2015,12 and ustekinumab (age ≥12
years) in 2015.13,14 Etanercept and adalimumab have been used
off-label in the United States for more than a decade, but
etanercept was approved by the US Food and Drug Adminis-
tration for use in children (age 4-17 years) in 201615 and
ustekinumab was approved (age ≥12 years) in 2017.16 Despite
the common use of methotrexate and tumor necrosis factor–
targeting biologics in children, to our knowledge, only metho-
trexate and adalimumab have been compared head-to-head
and prospectively.6 To gain insight into the relative reduction
in severity and real-world use of methotrexate and biologics
in pediatric plaque psoriasis, experts in the Psoriasis Investi-
gator Group of the Pediatric Dermatology Research Alliance and
the European Working Group on Pediatric Psoriasis retrospec-
tively assessed psoriasis severity scores and drug survival (rate
and duration of adherence to a specific drug) of methotrex-
ate and biologic agents.
Methods
Patient Selection
A multicenter, retrospective study in a real-world clinical prac-
tice setting was conducted by a consortium of 10 pediatric pso-
riasis centers in the United States and Canada and 10 centers
in Europe. To compare the improvement in psoriasis severity
of treatment with methotrexate vs biologics, the medical rec-
ords of all patients with moderate to severe plaque psoriasis
(determined by the treating physician) who used methotrex-
ate or a biologic, either alone or sequentially (but not concur-
rently), before their 18th birthday for at least 3 months be-
tween December 1, 1990, and September 16, 2014, and who had
at least a Minimal Core Data set (described below) recorded
were included.4 Each investigator's institutional review board
approved the protocol for this research by expedited or full re-
view. Written informed consent or assent was waived by each
investigator's institutional review board.
Design and Data Management
The Minimal Core Data set included information on patient and
treatment characteristics, net treatment duration, psoriasis se-
verity scores, and reason for drug discontinuation.4 Deiden-
tified data from each center were transmitted to a central
data coordinating center at Northwestern University, Chicago,
Illinois, and organized using Research Electronic Data Cap-
ture. The first patient was reviewed on September 1, 2014, and
the last patient was reviewed on July 31, 2015, with a final data
lock on December 14, 2015. Data analysis was performed from
December 14, 2015, to September 1, 2016.
Severity Scores
For analysis of psoriasis severity while the patients received
systemic treatment, results of the Psoriasis Area and Severity
Index (PASI), with a range from 0 to 72 (highest score indicat-
ing severe psoriasis), or Physician Global Assessment (PGA) had
to be available within 3 months of systemic medication initia-
tion and during at least 1 return visit at 0 to 2 months (defined
as 1-month visit), 2 to 4 months (defined as 3-month visit), or
4 to 8 months (defined as 6-month visit) after treatment ini-
tiation. The Psoriasis Area and Severity Index was directly re-
corded from the medical record. The Physician Global Assess-
ment was recorded from the medical record by the local
investigator based on the 6-point PGA score of 0 (clear), 1 (mini-
mal), 2 (mild), 3 (moderate), 4 (severe), and 5 (very severe).
If no PGA report was available but there was an abundant clini-
cal description of the extent and severity of the psoriasis, a cen-
tral reviewer assigned a PGA score (<5% of patients). The per-
centage of missing severity score data at each specific time
point was less than 10%.
Key Points
Question What is the association between use of methotrexate
vs biologics and psoriasis severity and drug survival (rate and
duration of adherence to a specific drug regimen) in pediatric
patients with moderate to severe psoriasis?
Findings In this cohort study including 234 pediatric patients with
moderate to severe psoriasis, those receiving biologics were more
likely than those treated with methotrexate to achieve a Physician
Global Assessment status of clear/almost clear and 75% or more
improvement of the Psoriasis Area and Severity Index rating at
6 months. In addition, biologics were associated with better drug
survival rates at 1, 3, and 5 years, with comparable discontinuation
rates owing to lack of response.
Meaning In pediatric patients with psoriasis, treatment with
biologics may be associated with a significantly greater reduction
in psoriasis severity than methotrexate; nevertheless, with 35.6%
of the patients achieving clear/almost clear and 40.0% reaching
75% or more improvement on the Psoriasis Area and Severity
Index, methotrexate remains an effective treatment for pediatric
psoriasis.
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Drug Survival
Drug survival was defined as the time that patients contin-
ued receiving a given drug using the technique of survival
analysis with the event of note being drug discontinuation.17-22
Three events for drug survival were defined and analyzed sepa-
rately: discontinuation in general, discontinuation owing to in-
effectiveness (defined as inadequate effect per physician or pa-
tient assessment), and discontinuation due to adverse events
(AEs). For each patient, the first methotrexate and/or biologic
treatment episode was analyzed. In accordance with other drug
survival studies, treatment interruption for up to 90 days
was allowed within a continuous treatment episode.18-21
Patients were included in PASI/PGA and drug survival analy-
ses until they (1) were lost to follow-up, (2) reached adult-
hood (≥18 years), (3) discontinued treatment owing to an event
other than the event of interest (suspected nonadherence and
maximum cumulative dose or treatment duration reached),
or (4) were still using the systemic agent at the time of the
final data lock.17 In the drug survival analyses these data were
censored (ie, only partial if no discontinuation date was
recorded).
Outcomes
Outcomes were defined as the percentage of patients treated
with either methotrexate or a biologic who achieved (1) PGA
rating of clear or almost clear (PGA 0/1) at 6 months after ini-
tiation, (2) 75% or greater improvement in PASI (PASI75)6,23 at
6 months, (3) PGA 0/1 and effect on mean PGA at some time
during the 6 months, and (4) PASI75 (and effect on mean PASI)
at some time during the 6 months (response over time). Sec-
ondary outcomes included 1-, 3-, and 5-year drug survival
for methotrexate and biologics and comparison between the
2 treatment groups of overall drug survival and drug survival
related to discontinuation owing to ineffectiveness.
Statistical Analysis
Demographic data were summarized as means (SDs) for
continuous variables and numbers and percentages for cat-
egorical variables. Psoriasis severity data (PGA and PASI) are
presented as means (SDs) and as number (percentage) of
patients achieving PGA 0/1 and PASI75.
Continuous and categorical data at baseline were com-
pared by independent-sample t test and categorical data by χ2
tests for independence or Fisher exact test if applicable. Con-
tinuous and categorical treatment episode data at baseline and
PGA and PASI scores at 6-month follow-up were compared by
generalized estimating equations to account for dependence
of measurements with different systemics used by patients who
were using more than 1 systemic agent sequentially during the
time of this study. The PGA and PASI responses in patients
treated with methotrexate or biologics at some time during the
6-month follow-up were studied by linear mixed modeling to
account for dependence of measurements with different sys-
temics when more than 1 agent was used sequentially during
the study period and for measurements at different times in 1
patient. Outcome measures were corrected for sex, age at treat-
ment start, disease duration, follow-up time, and psoriasis se-
verity at treatment start. The achievement of PGA 0/1 and of
PASI75 during follow-up was also analyzed by generalized es-
timating equation modeling to account for dependence of mea-
surements with different systemics used by patients who were
using more than 1 systemic agent sequentially during the time
of this study and for measurements at different time points in
1 patient. As with linear mixed modeling above, outcome mea-
sures were corrected for sex, age at treatment start, disease du-
ration, follow-up time, and psoriasis severity at treatment start.
Only patients with complete data for these factors were se-
lected for analyses (PGA: n = 177, PASI: n = 70).
Overall drug survival and drug survival related to discon-
tinuation owing to ineffectiveness were calculated for metho-
trexate and biologic agents using Kaplan-Meier estimates with
corresponding survival rates read from the Kaplan-Meier sur-
vival curves. Comparison of drug survival rates was analyzed
using multivariable Cox regression analysis. If patient or treat-
ment characteristics were significantly different between treat-
ment groups, variables were included for confounder correc-
tion. Possible confounders were added as covariates to the Cox
regression model. Sex, age at treatment start, and disease du-
ration were included as fixed variables in the model, indepen-
dent of significance values. Hazard ratios (HRs) with corre-
sponding P values (significant at <.05) resulting from the Cox
regression model were described. All analyses were per-
formed with SPSS, version 22.0 (IBM SPSS Inc).
Results
Study Patients
Of 446 pediatric patients in the full registry, 284 received
methotrexate and/or biologics. Among these, 27 patients were
excluded because of concomitant use of methotrexate and bio-
logics and 23 were excluded owing to lack of PGA and PASI
scores. In total, 210 children with plaque psoriasis were pre-
scribed single-agent therapy with methotrexate (n = 163) or bio-
logics (n = 47), and 24 children were sequentially treated with
methotrexate and biologics or vice versa (eFigure in the Supple-
ment). Of the 234 children treated with methotrexate and/or
biologics, 103 were boys (44.0%) and 131 were girls (56.0%).
Etanercept (52 [73.2%]) and adalimumab (14 [19.7%]) were
the most frequently prescribed biologics. Only 1 patient
(1.4%) was administered infliximab, and 4 patients (5.6%)
received ustekinumab. Given the few patients treated with
ustekinumab, the entire biologic cohort was used for PASI/
PGA scoring and survival analysis without further stratification.
Patient characteristics are reported in Table 1. Patients re-
ceiving methotrexate were younger at treatment onset com-
pared with patients receiving biologics (11.6 [3.7] vs 13.3 [2.9]
years; P = .002) and tended to have a shorter interval be-
tween age at diagnosis and initiation of systemic therapy (3.1
vs 4.1 years; P = .09). There was no significant difference in sex
and mean body mass index and body mass index percentile
between methotrexate- and biologic-treated patients. Among
children receiving biologics, 52.1% were from North America
(n = 37) and 47.9% were from Europe (n = 34). The ratio of
methotrexate to biologic use in North America vs Europe was
comparable (North America, 3.1:1 vs Europe, 2.1:1). Based on
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episodes of drug use (counting patients with sequential metho-
trexate and biologic use as 2 episodes), methotrexate was first-
line systemic therapy for psoriasis in 95.7% of methotrexate-
treated patients (n = 179), whereas a biologic was first-line in
64.8% (n = 46) of biologic-treated patients (eTable 1 in the
Supplement). Twenty-four children (10.2%) used both metho-
trexate and biologics sequentially, 23 of whom (95.8%)
switched from methotrexate to biologics (Table 1). All chil-
dren were included in the comparison of psoriasis severity
while receiving treatment. For those who used single-agent
therapy with methotrexate (n = 163), the mean (SD) start dos-
age was 0.28 (0.14) mg/kg per week and the mean maximum
dosage was 0.36 (0.15) mg/kg per week. For patients who were
sequentially treated with methotrexate and a biologic or vice
Table 1. Characteristics of 234 Patients With Plaque Psoriasis Who Were Treated With Methotrexate and Biologics, Alone or Sequentiallya
Characteristic





Agent Onlyb P Valuec
Sequential Methotrexate
and Biologic Agentd
or Vice Versa P Valuee
Patients, No. (%) 234 163 (69.7) 47 (20.1) 24 (10.2) NA
Continent NA
North America 148 (63.0) 111 (68.1) 33 (70.2)
.78
4 (16.7)
Europe 87 (37.0) 52 (31.9) 14 (29.8) 20 (83.3)
Sex NA
Male 103 (44.0) 68 (41.7) 17 (36.2)
.50
18 (75.0)
Female 131 (56.0) 95 (58.3) 30 (63.8) 6 (25.0)
Race NA
White 149 (63.7) 96 (58.9) 32 (68.1)
.94
20 (83.3)
Black or African American 8 (3.4) 7 (4.3) 1 (2.1) 0
Asian 6 (2.6) 4 (2.5) 1 (2.1) 1 (4.2)
Unknown or not reported 71 (30.3) 56 (34.4) 13 (27.7) 3 (12.5)
Ethnicity NA
Not Hispanic or Latino 104 (44.4) 70 (42.9) 21 (44.7)
.49
13 (54.2)
Hispanic or Latino 27 (11.5) 16 (9.8) 8 (17.0) 2 (8.3)
Unknown or not reported 103 (44.0) 77 (47.2) 18 (38.3) 9 (37.5)
BMI category (n = 102) (n = 89) (n = 85) (n = 17) (n = 12) NA
Underweight 6 (5.7) 6 (8.1) 0
.12
0
Normal weight 52 (49.5) 36 (48.6) 8 (44.4) 7 (58.3)
Overweight 18 (17.1) 11 (14.9) 7 (38.9) 0
Obesity 29 (27.6) 21 (28.4) 3 (16.7) 5 (41.7)
BMI percentile, mean (SD) 66.5 (32.2) 66.3 (32.5) 76.6 (26.1) .22 67.0 (31.3) NA
BMI, mean (SD) 21.4 (6.1) 21.4 (6.0) 24.6 (7.5) .06 22.3 (7.4) NA
Age at diagnosis, mean (SD), y 8.7 (3.8) 8.6 (3.8) 9.1 (3.9) .46 8.0 (3.5) NA
Age at start of systemic therapy, mean (SD), y NAf 11.6 (3.7) 13.3 (2.9) .002 Methotrexate: 12.0 (2.9)
Biologic: 13.3 (3.1)
.002
Disease duration, mean (SD), y NAf 3.1 (3.4) 4.1 (3.3) .09 Methotrexate: 4.0 (3.2)
Biologic: 5.3 (3.2)
.001
Treatment duration, mean (SD), y NAf 1.6 (1.8) 1.8 (1.6) .39 Methotrexate: 1.1 (1.0)
Biologic: 1.4 (1.4)
.46
Naive for systemic medication/previously used
systemic medication
NAf 159 (97.5) 45 (95.7) .62 Methotrexate: 20 (83.3)
Biologic: 1 (4.2)
.001
Naive for biologic agents/previously used
biologic agentsg
NAf 163 (100.0) NA NA Methotrexate: 23 (95.8)
Biologic: NA
NA
Naive for methotrexate/previously used
methotrexated
NAf NA 47 (100.0) NA Methotrexate: NA
Biologic: 1 (4.2)
NA
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided
by height in meters squared); NA, not applicable.
a Patients could have been previously treated with conventional systemic
agents (except methotrexate). However, patients were treated at any one
time with a single systemic medication.
b Etanercept was the most frequently prescribed biologic (32 [68.1%]) followed
by adalimumab (11 [23.4%]), ustekinumab (3 [6.4%]), and infliximab (1 [2.1%]).
c Comparison of patients who received single-agent therapy with methotrexate
or a biologic. Continuous data were compared by independent-samples t test
and categorical data by χ2 tests for independence or Fisher exact test if
applicable.
d Etanercept was the most frequently prescribed biologic (20 [83.3%]) followed
by adalimumab (3 [12.5%]) and ustekinumab (1 4.2%]).
e Continuous and categorical data were compared by generalized estimating
equations to account for dependence of measurements with different
systemics used by 1 patient.
f Mean could not be calculated for the total group because 24 patients were
treated sequentially with methotrexate and biologic agents or vice versa.
g Of 24 patients, 23 switched from methotrexate to biologics and 1 switched
from biologics to methotrexate.
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versa (n = 24), the mean starting dosage was 0.24 (0.10) mg/kg
per week and the mean maximum dosage was 0.29 (0.11) mg/kg
per week. Although numbers were small, there was a dispro-
portional representation of obese children among those who
switched from methotrexate to biologics (5 of 12 patients
[41.7%]). More than 90% of biologic use occurred after Euro-
pean Medicines Agency approval of etanercept and publica-
tion of the pivotal pediatric study in January 20087 (the drug
was commercially available in the United States starting in
2004) and during the last quarter of the study period (Decem-
ber 2008 to September 2014) (eTable 2 in the Supplement).
Psoriasis Severity
Without correction for confounders, at 6 months, PASI75 was
achieved in 12 of 30 patients (40.0%) receiving methotrexate
and 20 of 28 patients (71.4%) receiving biologics (P = .02). In
addition, achievement of PGA 0/1 tended to be higher with bio-
logics (18 of 37 patients [48.6%]) than methotrexate (41 of 115
patients [35.6%]) but did not reach statistical significance
(P = .15) (Table 2). After correction for potential confounders
(psoriasis severity at baseline, follow-up, sex, age at treat-
ment start, and disease duration), achievement of PGA 0/1 and
PASI75 from baseline through 6 months was more likely with
biologics vs methotrexate (Table 3 and eTable 3 in the Supple-
ment) (PGA 0/1: odds ratio [OR], 2.00; 95% CI, 0.98-4.00;
P = .06; PASI75: OR, 4.56; 95% CI, 2.02-10.27; P < .001). Re-
duction in mean PGA and PASI scores with biologics com-
pared with methotrexate was also greater throughout the
6-month treatment (Table 3 and eTable 4 in the Supplement)
(PGA effect, −0.31; 95% CI, −0.56 to −0.06; P = .02; PASI ef-
fect, −3.13; 95% CI, −4.33 to −1.94; P < .001). These data sug-
gest that a greater reduction in psoriasis severity with biolog-
ics occurs within 6 months after initiation.
At data lock, 66 of 187 patients (35.3%) had discontinued
methotrexate treatment, most frequently for ineffectiveness
(36 [19.3%]), occurrence of AEs (22 [11.8%]), and treatment non-
adherence reported by the patient and/or family (7 [3.7%]).
Sixteen of 71 patients (22.5%) discontinued a biologic primar-
ily because of ineffectiveness (11 [15.5%]) or AE occurrence
(4 [5.6%]).
Drug Survival
For drug survival, 265 treatment episodes were included
(methotrexate, n = 187; biologics, n = 71). As depicted in the
Figure, A, 77.5% of patients continued to receive methotrex-
ate after 1 year, 50.3% after 3 years, and 35.9% after 5 years.
The median overall survival duration for methotrexate was
36.0 months (95% CI, 23.07-49.53). The median drug sur-
vival related to discontinuation owing to ineffectiveness was
73.6 months (95% CI, 32.19-115.04). The overall drug survival
for biologics was 83.4% after 1 year, 64.3% after 3 years, and
57.1% after 5 years (Figure, A). Median drug survival times for
biologic agents could not be estimated because more than
50% of the patients were still receiving the drug at the end of
the study.
Biologic agents had a longer confounder-corrected drug
survival than methotrexate (HR, 2.23; 95% CI, 1.21-4.10; P = .01)
(eTable 5 in the Supplement). Confounder-corrected drug sur-
vival owing to ineffectiveness was comparable between groups
(HR, 1.64; 95% CI, 0.80-3.36; P = .18), whereas discontinua-
tion due to AEs occurred more frequently with methotrexate
compared with biologics (HR, 4.67; 95% CI, 1.08- 20.26;








Patients, No. (%) NA
PGA 0/1 Methotrexate 115 0 41 (35.6)
.15
Biologice 37 0 18 (48.6)
PASI75 Methotrexate 30 NA 12 (40.0)
.02
Biologicf 28 NA 20 (71.4)
Severity scores, mean (SD)
PGA Methotrexate 115 3.6 (0.7) 1.9 (1.1) 1.6 (1.2)
.32
Biologice 37 3.6 (0.8) 1.8 (1.2) 1.9 (1.2)
PASI Methotrexate 30 11.8 (6.2) 5.0 (5.1) 6.8 (4.7)
.02
Biologicf 28 13.7 (7.7) 3.1 (2.4) 10.6 (7.4)
Abbreviations: PASI, Psoriasis Area and Severity Index; PASI75, 75% or greater
improvement in PASI; PGA, Physician Global Assessment.
a Patients could have been previously treated with conventional systemic
agents except methotrexate. However, patients were treated at any 1 time
with a single systemic medication.
b Participating sites provided PASI and/or PGA scores at medication initiation
and during at least 1 follow-up visit. Patient numbers are therefore not
identical in both groups.
c PASI scores were determined using a range of 0 to 72, with the highest score
indicating severe psoriasis, and/or PGA scores were determined using a scale
of 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), and 5 (very severe)
at medication initiation.
d Continuous (ΔPGA and ΔPASI) and categorical (PGA 0/1 and PASI75) data were
compared with generalized estimating equations to account for dependence
of measurements with different systemic agents used at different times during
the study period. The probability of methotrexate or biologic was estimated as
a function of the characteristic.
e Etanercept was the most frequently prescribed biologic (27 [73.0%]) followed
by adalimumab (7 [18.9%]), ustekinumab (2 [5.4%]), and infliximab (1 [2.7%]).
f Etanercept was the most frequently prescribed biologic (21 [75.0%]) followed
by adalimumab (3 [10.7%]) and ustekinumab (4 [14.3%]).
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P = .04). Overall, 22 of 187 patients receiving methotrexate and
4 of 71 patients receiving biologics discontinued treatment be-
cause of a distinct, nonserious AE thought possibly to be drug
related. Among children receiving methotrexate, these AEs
most often were liver function test results outside of the ref-
erence ranges (n = 5), nausea (n = 5), fatigue (n = 4), and in-
fections (n = 4). In children who discontinued biologics, AEs
were abdominal discomfort (n = 1), vomiting (n = 1), fatigue
(n = 1), and upper respiratory infection (n = 1).
Discussion
Data on real-world effectiveness in childhood psoriasis are
limited5-7,10 and, to our knowledge, only 1 prospective trial com-
pared methotrexate with a biologic (adalimumab).6 Our ret-
rospective, real-world study in a large cohort of North Ameri-
can and European children with moderate to severe plaque
psoriasis focused on the outcome of treatment and drug sur-
vival of methotrexate vs biologics—the 2 most commonly pre-
scribed therapies.
In the 16-week comparative trial of weekly oral metho-
trexate, 0.1 to 0.4 mg/kg per week (37 patients), vs every-2-
weeks adalimumab, 0.8 mg/kg (38 patients), 60.5% of the pa-
tients receiving adalimumab vs 40.5% of those receiving
methotrexate achieved PGA 0/1 (P = .08) and 57.9% vs 32.4%
achieved PASI75 (P = .03).6 These prospective results may have
underestimated the efficacy of methotrexate, given the short
duration (peak efficacy of methotrexate at 6 months5 or even
32-52 weeks of subcutaneous methotrexate in adults24) and
low mean dosages of methotrexate 0.15 mg/kg per week, which
is based on the mean dosage 8.0 mg/week and mean weight
of 53 kg; the real-world methotrexate dosage is 0.2 to 0.7 mg/kg
per week at initiation with a taper as tolerated. However, PASI75
was achieved in only 33.3% of 25 children treated with metho-
trexate, 0.2 to 0.4 mg/kg per week (median dosage, 15 mg/
week), for 24 weeks in the daily practice Child-CAPTURE
registry.5,25 Our study showed a 6-month PASI75 of 40.0% with
a mean methotrexate dosage of 0.29 (0.14) mg/kg per week
(maximum, 0.36 [0.15] mg/kg per week) (Table 2 and Table 3),
which is within the recommended guidelines for dosing.25,26
While most children were administered oral methotrexate, dif-
ferences and transitions between the use of oral vs subcuta-
neous methotrexate were not captured.
The children’s responses to etanercept, the most com-
mon biologic in our population (52 [73.2%]) compared well with
data from other pediatric etanercept studies. The PGA 0/1
(57.0%) and PASI75 (69.0%) scores at week 24 and through 264
weeks of monitoring in a study of etanercept, 0.8 mg/kg per
week, in North American children aged 4 to 17 years with mod-
erate to severe plaque psoriasis and maintained through week
264 were comparable with our findings.7-9 Twenty-three chil-
dren (65.2%) aged 4 to 17 years in another real-world practice
setting study achieved PASI75 at 24 weeks and reported sus-
tained improvement through week 52.27
We also studied the pattern of response throughout the
6 months of follow-up. After correction for confounding fac-
tors and inclusion of all available follow-up visits, a higher like-
lihood of achieving PGA 0/1 or PASI75 at some time during the
6 months was shown for biologic-treated patients compared
with methotrexate-treated children (Table 3) (PGA 0/1: OR,
2.00; 95% CI, 0.98-4.00; P = .06; PASI75: OR, 4.56; 95% CI,
2.02-10.27; P < .001), with greater reductions in absolute PGA
and PASI scores.
Among children receiving biologics, 52.1% were from North
America (n = 37) and 47.9% were from Europe (n = 34), reflect-
ing off-label biologics use in North American patients (data lock
before the 2016 US Food and Drug Administration approval)
(eTable 1 in the Supplement). Most European children who re-
ceived biologics switched from methotrexate to biologics (20
Table 3. Psoriasis Severity Through 6-Month Follow-up by Treatment Group for PGA and PASI
Treatment









Methotrexate 135 1 [Reference] 36 1 [Reference] 135 0 [Reference] 36 0 [Reference]
Biologic 42e 2.00 (0.98 to 4.00) 34f 4.56 (2.02 to 10.27) 42e −0.31 (−0.56 to −0.06) 34f −3.13 (−4.33 to −1.94)
P Value .06 <.001 .02 <.001
Abbreviations: PASI, Psoriasis Area and Severity Index; PASI75, 75% or greater
improvement in PASI; PGA, Physician Global Assessment.
a Methotrexate treatment could have been preceded by other conventional
systemics or biologic agents. Treatment with biologics could have been
preceded by conventional systemics (including methotrexate) or other
biologic agents. However, patients were treated at any one time with a single
systemic medication.
b Participating sites provided PASI and/or PGA scores at medication initiation
and during at least 1 follow-up visit. Patient numbers are therefore not
identical in both groups. The percentage of missing data was less than 10%
at each time point.
c The association between medication and severity scores during follow-up was
studied by general estimating equation modeling. Patients who received
methotrexate and biologics at different times were included in both treatment
groups. Sex, age at treatment start, and disease duration did not influence the
results and were therefore not included in the model. Follow-up (months) and
psoriasis severity scores at the start of treatment also had an association with
psoriasis severity at some point during 6-month follow-up (eTables 3 and 4 in
the Supplement). There was no interaction between follow-up duration and
medication. Severity score at the start of treatment refers to the
corresponding PASI and/or PGA score at medication initiation.
d Etanercept was the most frequently prescribed biologic (29 [69.0%])
followed by adalimumab (10 [23.8%]), ustekinumab (2 [4.8%]), and infliximab
(1 [2.4%]).
e Etanercept was the most frequently prescribed biologic (25 [73.5%]) followed
by adalimumab (5 [14.7%]) and ustekinumab (4 [11.8%]).
f The association between medication and severity scores during follow-up was
studied by linear mixed modeling. Patients who received methotrexate and
biologics at different times were included in both treatment groups. Sex, age
at treatment start, and disease duration did not influence the results and were
therefore not included in the model. Follow-up (months) and psoriasis severity
scores at the start of treatment also had an association with psoriasis severity
through the 6-month follow-up period (eTable 4 in the Supplement). There
was no interaction between follow-up duration and medication.
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of 34 [58.8%]). In contrast, most children in North America who
received biologics had received no previous systemic medi-
cation (32 of 37 [86.5%]), possibly reflecting greater comfort
of physicians and parents with the lower perceived risk and
venipuncture requirements of biologic use (eTable 2 in the
Supplement). Etanercept was US Food and Drug Administra-
tion approved for adults in 2004 and the first placebo-
controlled study with etanercept in pediatric psoriasis began
in 2004.7 The availability and greater experience with etaner-
cept among those of us affiliated with North American insti-
tutions (A.S.P., D.P.W., I.L.-C., M.M.T., W.L.T., M.H., L.B., E.S.,
R.A.V., K.H., and K.M.C.) and several of these institutions or
investigators were in the pivotal trial (Chicago, San Fran-
cisco, San Diego, Toronto, St. Louis), likely contributed to the
prescription of biologics in North American children without
prior use of methotrexate (9 [27.3%]). Consistently, most treat-
ment episodes began after closure of the etanercept trial (23
[69.7%]).
To our knowledge, this is the first study to compare drug
survival rates and the real-world utility profiles of methotrex-
ate and biologics in pediatric psoriasis. Drug survival is a com-
prehensive marker of drug effectiveness, safety, and real-
world utility, including patient and physician preferences.17 The
overall 3-year drug survival rates of methotrexate and biolog-
ics were 50.3% and 64.3%, respectively (Figure). Multivari-
ate Cox regression analysis of drug survival corrected for con-
founders showed that biologics had better overall drug survival
than methotrexate (HR, 2.23; 95% CI, 1.21-4.10; P = .01). Rea-
sons for drug discontinuation are often a negative event, such
as ineffectiveness or the occurrence of AEs. Drug survival of
both treatment groups was determined predominantly by dis-
continuation owing to ineffectiveness. Although ineffective-
ness was higher for methotrexate (19.3%) vs biologics (15.5%),
the difference did not reach statistical significance.
Methotrexate drug survival has been described in 2 other
pediatric psoriasis cohorts.5,28 The 1-year overall drug sur-
vival of methotrexate, described by van Geel et al,5 was 72.0%,
comparable to our results (77.5%). Ergun et al28 showed sub-
stantially lower methotrexate survival rates, but direct com-
parison with our data is hindered by differences in event defi-
nition and prescription of higher methotrexate doses. Although
the percentages of overall drug survival were not stated, cal-
culated 1-year (42.9%) and 3-year (11.4%) drug survival rates
in another study of biologics in pediatric psoriasis were lower
than our results.29
Limitations
Our retrospective analysis was limited by lack of standardiza-
tion in clinical approach (eg, availability of different treat-
ments, dosages, and treatment schedule) and follow-up vis-
its. In addition, most patients did not have results from both
measures (PGA and PASI), introducing possible reporting bias.
Although the PGA score was based on recorded information,
investigators were asked to adjust data to a single 6-point scale
(clear to very severe) vs the use by some of a 5-point scale (clear
to severe), which could have underestimated the percentage
of very severe disease. An additional limitation in determin-
ing drug survival was the failure to specifically collect infor-
mation about whether physician perception of greater effi-
cacy and safety of biologics induced the change from
methotrexate to a biologic. Results of the pivotal studies of
etanercept in childhood psoriasis were first reported in 2008,
Figure. Drug Survival of Methotrexate (n = 187) and Biologic Agents
(n = 71) for Pediatric Psoriasis
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A, Overall survival. B, Drug survival for discontinuation owing to ineffectiveness.
C, Drug survival for discontinuation due to an adverse event (AE). Median drug
survival time for methotrexate was 36.0 months ([95% CI, 23.07-49.53).
Median drug survival for biologic agents could not be estimated, as more than
50% of the patients were still receiving the drug at the end of the study.
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in the middle of the study period, and etanercept became com-
mercially available and on-label shortly thereafter for chil-
dren in Europe and was available already for adults in the Eu-
ropean Union, United States, and Canada. In addition, further
stratification to compare biologics was not feasible, given the
small numbers.
Conclusions
The approval of targeted therapies for pediatric psoriasis and
publication of results from clinical trials and daily clinical
practice cohorts are altering the treatment landscape for
patients. Our international, retrospective cohort study
appears to support a greater reduction in psoriasis severity
from use of biologics compared with methotrexate in a real-
world practice setting and showed a longer overall drug sur-
vival. In addition to their documented efficacy, biologics are
convenient to use, require less monitoring, and are associ-
ated with fewer treatment-related toxic effects than conven-
tional agents in children, making them an attractive treat-
ment option.3,4,16 Nevertheless, biologics are much more
costly than methotrexate, even with the required laboratory
monitoring for the latter, and methotrexate still has an
important position in the treatment of pediatric psoriasis.
Prospective comparative analyses with uniform data record-
ing will be important for future real-world practice studies
that complement data from randomized clinical trials.
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